Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these figures provides insight into the shifting landscape of the pharmaceutical ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA ® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Still, it remains an iconic brand with some of the most cutting edge TVs out there. It pushes the envelope with its QD-OLED technology, whilst offering some of the brightest and boldest QLED TVs.

Cigna recorded more high-cost claims due to increased usage of specialty medications such Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda and other inpatient surgeries like ...

What's in a name? A lot, actually. The right brand name can make your business stand out, connect with customers emotionally, and convey what you're all about. But choosing that perfect moniker is ...

The aim of the data-powered offering is to identify consumers who are predicted to be in the market for a brand’s product or service within the next three months. Marketers can use Brand+ to ...